PolyPeptide Group Stock

PolyPeptide Group ROCE

The Return on Capital Employed (ROCE) of PolyPeptide Group (PPGN.SW) as of Aug 16, 2026 is 2.18 %. In the previous year, Return on Capital Employed (ROCE) was -2.06 % — a change of -205.67% (higher).

ROCE

2.18 %

YoY

-205.67%

Last updated:

In 2026, PolyPeptide Group's return on capital employed (ROCE) was 2.18 %, a -205.67% increase from the -2.06 % ROCE in the previous year.

Access this data via the Eulerpool API

PolyPeptide Group Stock analysis

What does PolyPeptide Group do? PolyPeptide Group AG is a leading company in peptide chemistry and offers customized peptide solutions for a variety of applications to its customers. The company was founded in 1994 and is headquartered in Zurich, Switzerland. PolyPeptide has branches in seven countries and operates worldwide in over 80 countries. The company works with customers from various industries, including the pharmaceutical industry, biotechnology, diagnostics, as well as cosmetics and food industries. With many years of experience, a deep understanding of peptide chemistry, and state-of-the-art technologies, PolyPeptide is able to offer its customers first-class and tailor-made peptide solutions. PolyPeptide is divided into three divisions: Generics, Innovative Peptides, and Peptide Manufacturing. In the Generics division, the company offers a wide range of generic peptides that can be used for various applications. These peptides are manufactured to the highest quality standards and are cost-effective alternatives to expensive proprietary peptides. The Innovative Peptides division offers customized peptide solutions for specific applications. These peptides are developed in close collaboration with customers and can be used for the treatment of cancer, autoimmune diseases, diabetes, and other conditions. The third division, Peptide Manufacturing, specializes in the production of peptides for clinical studies and commercial production. PolyPeptide has modern production facilities and strict quality controls to ensure that the peptides meet the highest quality standards. PolyPeptide's business model is based on close collaboration with customers and partners to develop tailor-made peptide solutions. The company works closely with its customers to understand their requirements and develop suitable peptides for their specific applications. PolyPeptide has an experienced team of scientists and technicians specialized in peptide synthesis and continuously focuses on the latest knowledge in peptide chemistry. PolyPeptide offers a wide range of products, including generic peptides for research purposes, customized peptides for specific applications, peptides for clinical studies, and for commercial production. The company has a wealth of experience in peptide chemistry and has acquired numerous patents for its technologies and methods. In summary, PolyPeptide Group AG is a leading company in peptide chemistry. The company offers customized peptide solutions for a variety of applications and has extensive experience in manufacturing peptides for the pharmaceutical industry, biotechnology, diagnostics, cosmetics, and food industry. Through its close collaboration with customers and state-of-the-art technologies, PolyPeptide is able to offer its customers first-class and cost-effective peptide solutions, solidifying its position as a leader in peptide chemistry. PolyPeptide Group is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling PolyPeptide Group's Return on Capital Employed (ROCE)

PolyPeptide Group's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing PolyPeptide Group's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

PolyPeptide Group's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in PolyPeptide Group’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about PolyPeptide Group stock

Return on Capital Employed (ROCE) of PolyPeptide Group is 2.18 % in 2026.

Return on Capital Employed (ROCE) of PolyPeptide Group changed from -2.06 % to 2.18 %, representing a -205.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) PolyPeptide Group since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s PolyPeptide Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

Profitability — PolyPeptide Group

All Key Metrics — PolyPeptide Group